ESPE Abstracts

Introduction: Vosoritide, a C-type natriuretic peptide analog, has emerged as the first therapeutic agent approved to enhance growth velocity in individuals with achondroplasia (ACH).Aim: To assess growth response to vosoritide in children with ACH under the care of a specialized multidisciplinary team (MDT).Methods: A retrospective study was conducted in our center on children dia...